On Monday, April 15, the US Supreme Court heard oral arguments on whether genetic material is patent eligible subject matter and in particular, whether Utah-based Myriad Genetics’ patents covering isolated human genes linked to breast and ovarian cancer are valid and enforceable.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Myriad, gene patents, US Supreme Court, oral arguments, BRCA1
